Generex Biotechnology
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Generex Biotechnology generated cash of -$6,121,259, which is more than the previous year. Cash used in financing activities reached the amount of $5,810,457 last year. Net change in cash is therefore -$283,033.
Cash Flow
| 2012 | -8.04M | 4.77M | 746.47K |
|---|---|---|---|
| 2013 | -3.66M | 1.68M | 3.46M |
| 2014 | -3.57M | 794.29K | 4.35M |
| 2015 | -2.88M | -90.98K | 481.41K |
| 2016 | -775.48K | 0 | 52.95K |
| 2017 | -1.17M | 12.36K | 4.03M |
| 2018 | -2.29M | -8.55K | 453.69K |
| 2019 | -9.57M | 2.31M | 6.50M |
| 2020 | -6.12M | 44.68K | 5.81M |
GNBT Cash Flow Statement (2012 – 2020)
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 298.48K | 1.04M | 2.87M | 16.89K | 749.96K | 3.26M | 1.70M | 246.30K | 2.79M |
Operating activities | |||||||||
Net income | -34.23M | -11.00M | 35.94M | -76.83M | -3.22M | -2.19M | -1.41K | -8.55M | -9.49M |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||||
Depreciation and amortization | 1.00M | 426.44K | 23.78K | 5.04K | 265.21K | 380.68K | 368.44K | 463.71K | 612.65K |
Stock-based compensation expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 837.75K | 130.54K |
| Deferred income tax benefit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 837.75K | 130.54K |
| Changes in operating assets and liabilities: | |||||||||
Accounts receivable, net | -6.27K | -750.24K | -33.55K | 980 | 0 | 0 | 0 | 0 | 8.47K |
Inventories | -113.17K | 1.12M | -2.04K | 11.10K | 0 | 0 | 0 | 0 | 716.39K |
Accounts payable | 9.50M | 10.72M | 872.16K | 977.41K | 1.05M | -117.73K | -490.35M | -1.21B | 0 |
Cash generated by operating activities | -6.12M | -9.57M | -2.29M | -1.17M | -775.48K | -2.88M | -3.57M | -3.66M | -8.04M |
Investing activities | |||||||||
Purchases Of Investments | 0 | 0 | 0 | -4M | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -4.61K | -316.40K | -8.55K | 0 | 0 | -90.98K | -89.48K | -78.94K | -2.41K |
Acquisitions Net | 49.30K | 2.28M | 320K | 12.36K | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 44.68K | 2.31M | -8.55K | 12.36K | 0 | -90.98K | 794.29K | 1.68M | 4.77M |
Financing activities | |||||||||
Common Stock Issued | 109.77K | 2B | 0 | 3M | 4.5K | 133K | 286.78M | 699.44M | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 403.07M | 0 | 0 |
Repayments of term debt | -935.73K | 0 | 0 | 0 | 0 | 0 | -606.80K | -1.83M | -4.82M |
Cash used in financing activities | 5.81M | 6.50M | 453.69K | 4.03M | 52.95K | 481.41K | 4.35M | 3.46M | 746.47K |
Net Change In Cash | -283.03K | -747.88K | -1.83M | 2.86M | -733.06K | -2.51M | 1.56M | 1.46M | -2.55M |
Cash at end of period | 15.45K | 298.48K | 1.04M | 2.87M | 16.89K | 749.96K | 3.26M | 1.70M | 246.30K |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |